A randomized controlled trial of combined pathological evidence and lifestyle intervention for the treatment of phlegm-damp internal obstruction type borderline hypertension

Eye Hospital of China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•?No antihypertensive medication in the last 4 weeks and three consecutive upper limb brachial artery sitting blood pressure measurements on non-same day within 1 week, systolic blood pressure (SBP) 120-139 mmHg and/or diastolic blood pressure (DBP) 80-89 mmHg.
•?Age 18-65 years old, gender not limited.
•?Meet the diagnostic criteria of phlegm-dampness internal obstruction evidence.
•?Voluntary participation and cooperation with the investigator by signing the written informed consent.

•?People with definite primary and secondary hypertension.
•?Participating in other clinical researchers.
•?People with borderline hypertension who are taking western antihypertensive drugs.
•?People with acute coronary syndrome, acute attack of chronic heart failure, malignant arrhythmia, heart valve disease, cardiomyopathy and other serious cardiovascular diseases.
•?People with acute or severe cerebrovascular diseases such as cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction and transient ischemic attack.
•?People with severe liver or kidney dysfunction and conditions judged by the investigator to be inappropriate for enrollment.
•?Pregnant and lactating women.
•?Allergic or allergic to multiple drugs.

发起方

Eye Hospital of China Academy of Chinese Medical Sciences